Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.

Abstract

BACKGROUND:

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in patients with UC in a real-life population cohort for comparison with the tofacitinib UC clinical trial program.

METHODS:

Clinical trial-like criteria were applied to an IBM MarketScan® claims database population-based cohort (n = 22,967) of patients with UC (October 2010 to September 2015) to identify a UC trial-like cohort treated with tumor necrosis factor inhibitors (TNFi; n = 6366) to compare with the tofacitinib UC clinical trial cohort (n = 1157).

RESULTS:

Incidence rates (events per 100 patient-years; [95% confidence interval]) in the UC trial-like cohort were as follows: serious infections, 3.33 (2.73-4.02); opportunistic infections (OIs; excluding herpes zoster [HZ]), 1.45 (1.06-1.93); HZ, 1.77 (1.34-2.29); malignancies (excluding nonmelanoma skin cancer [NMSC]), 0.63 (0.43-0.90); NMSC, 1.69 (1.35-2.10); major adverse cardiovascular events (MACE), 0.51 (0.31-0.79); pulmonary embolism (PE), 0.54 (0.30-0.89); deep vein thrombosis (DVT), 1.41 (1.00-1.93); and gastrointestinal perforations, 0.31 (0.16-0.54). Compared with the UC trial-like cohort, tofacitinib-treated patients had numerically lower incidence rates for serious infections (1.75 [1.27-2.36]), OIs (excluding HZ; 0.16 [0.04-0.42]), NMSC (0.78 [0.47-1.22]), PE (0.16 [0.04-0.41]), and DVT (0.04 [0.00-0.23]), and a higher rate for HZ (3.57 [2.84-4.43]); rates for malignancies (excluding NMSC), MACE, and gastrointestinal perforations were similar.

CONCLUSIONS:

When acknowledging limitations of comparing claims data with controlled clinical trial data, incidence rates for HZ among TNFi-treated patients in the UC trial-like cohort were lower than in the tofacitinib UC clinical trial cohort; rates for serious infections, OIs, NMSC, PE, and DVT were numerically higher.

CLINICALTRIALS.GOV:

NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612.

• Authors: Jeffrey R Curtis, Miguel Regueiro, Huifeng Yun, Chinyu Su, Marco DiBonaventura, Nervin Lawendy, Chudy I Nduaka, Nana Koram, Joseph C Cappelleri, Gary Chan, Irene Modesto, Gary R Lichtenstein
• Journal: Inflammatory bowel diseases (Inflamm Bowel Dis) Vol. 27 Issue 9 Pg. 1394-1408 (08 19 2021) ISSN: 1536-4844 [Electronic] England
• PMID: 33324993 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Chemical References

• Piperidines
• Pyrimidines
• tofacitinib

Topics

• Colitis, Ulcerative (drug therapy, epidemiology)
• Humans
• Neoplasms
• Opportunistic Infections
• Piperidines (therapeutic use)
• Product Surveillance, Postmarketing
• Pyrimidines (therapeutic use)
• Randomized Controlled Trials as Topic